Echo Therapeutics (ECTE) 1.91 $ECTE
IRadimed (IRMD) Jumps: Stock Moves 7.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:25AM CDT
IRadimed (IRMD) was a big mover last session, with shares rising over 7% on the day.
Mazor Robotics (MZOR) Jumps: Stock Moves 6.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 8:25AM CDT
Mazor Robotics (MZOR) was a big mover last session, with shares rising nearly 7% on the day.
The Zacks Analyst Blog Highlights: Medtronic, Covidien, Bacterin International Holdings, Inogen and Echo Therapeutics
PR Newswire - Wed Sep 03, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Medtronic Inc. (NYSE:MDT-Free Report), Covidien plc (NYSE:COV-Free Report), Bacterin International Holdings, Inc. (AMEX:BONE-Free Report), Inogen, Inc. (Nasdaq:INGN-Free Report) and Echo Therapeutics, Inc. (Nasdaq:ECTE-Free Report).
3 Top-Ranked Medical Equipment Stocks to Buy Now - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 1:08PM CDT
The fiscal 2015 budget for the Department of Health and Human Services (HHS) has brought a fresh lease on life to the U.S. healthcare economy, following the past years' debacle.
Echo Therapeutics Sees Narrower Loss but Lags Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 8:20AM CDT
Thanks to the cost reduction measures that were successfully implemented in September last year by Echo Therapeutics (ECTE)
Echo Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Thu Aug 14, 3:30PM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced its financial results for the quarter ended June 30, 2014 and provided a business update. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, is available by visiting the Investors section of Echo's website at www.echotx.com.
Platinum Delivers Letter To Echo Therapeutics, Inc. Demanding To Inspect Certain Books And Records Under Delaware Law
PR Newswire - Wed Jul 23, 6:44PM CDT
An affiliate of Platinum Management (NY) LLC ("Platinum"
has delivered a letter to Echo pursuant to Section 220 of the Delaware General Corporation Law demanding to inspect certain books and records of Echo Therapeutics, Inc. ("Echo" or the "Company" (NASDAQ: ECTE) relating to possible mismanagement, breaches of fiduciary duty and wrongdoing by, among others, members of the Board and the Company's current interim CEO, Kimberly A. Burke. Platinum, together with certain of its affiliates, is the largest stockholder of the Company owning approximately 30% of the outstanding Common Stock on a fully converted basis.
Platinum Reports On Town Hall Meeting For Echo Therapeutics, Inc. Stockholders
PR Newswire - Tue Jul 22, 10:26AM CDT
Platinum Management (NY) LLC and certain affiliates ("Platinum" , which beneficially hold approximately 30.34% of the shares of Echo Therapeutics, Inc. ("Echo" or the "Company" (NASDAQ: ECTE) on a fully converted basis, today reported on the Town Hall Meeting it recently hosted for the concerned stockholders of Echo. All Company directors and stockholders were invited to attend the Town Hall Meeting, but sadly directors Vincent D. Enright, William F. Grieco and James F. Smith (the "Lingering Directors" did not participate despite the dire need for immediate change at Echo.
Disturbing Self-Dealing By Repudiated Echo Directors Forces Platinum To Exercise Contractual Right To Call Special Meeting; Town Hall Meeting Also Planned
PR Newswire - Thu Jul 10, 4:14PM CDT
Platinum Management (NY) LLC and certain affiliates ("Platinum" , the largest stockholder of Echo Therapeutics, Inc. (NasdaqCM: ECTE) ("Echo" or the "Company" owning approximately 20% of the Company's outstanding Common Stock, sent a letter to the Company today exercising Platinum's contractual right under the December 10, 2013 Stock Purchase Agreement between Platinum and the Company to cause Echo to call a meeting of stockholders to vote to lift the "blockers" limiting Platinum's voting power.
Echo Announces Election Of New Board Member At Annual Meeting Of Stockholders
PR Newswire - Thu Jun 19, 3:07PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that, based on preliminary results provided by Echo's proxy solicitor, stockholders have elected Shepard M. Goldberg as a new member of the Echo Board of Directors at the 2014 Annual Meeting of Stockholders held on Thursday, June 19, 2014. These preliminary results are subject to receipt of the official confirmation by the independent inspector of elections, IVS Associates, Inc., which is expected to be received early next week.
Echo Therapeutics, Inc. Announces 2013 Financial Results
PR Newswire - Thu Mar 27, 6:50AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced financial results for the year ended December 31, 2013. Echo's Annual Report on Form 10-K, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com on March 28, 2014 after the close of the financial markets.
Echo Therapeutics Schedules 2013 Financial Results for Thursday, March 27, 2014
PR Newswire - Thu Mar 20, 8:35AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it will release financial results for the year ended December 31, 2013 on Thursday, March 27, 2014. Management will hold a conference call to review the company's 2013 performance starting at 9:00 a.m. ET on the same day.
4 Stocks Under $10 Making Big Moves
at The Street - Mon Mar 17, 6:46AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Echo Therapeutics to Exhibit at the ISICEM 2014 Critical Care Conference
PR Newswire - Thu Mar 06, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo" , a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its clinical study of Symphony was selected for poster presentation at the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM) from March 18-21, 2014 in Brussels, Belgium.
Echo Therapeutics to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Mon Mar 03, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo" , a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics, will present at the upcoming 26th Annual ROTH Capital Conference.
Echo Therapeutics names Michael M. Goldberg to board
M2 - Mon Mar 03, 6:33AM CST
Us-based medical device company Echo Therapeutics Inc (Nasdaq:ECTE) announced on Friday the appointment of Michael M Goldberg, MD, to the company's board of directors.
Echo Therapeutics elects Dr Michael M. Goldberg to board
M2 - Mon Mar 03, 5:21AM CST
Medical device company Echo Therapeutics (NasdaqCM:ECTE) revealed on Friday that Dr Michael M. Goldberg, MD has been appointed to its board of directors.
Echo Therapeutics Adds New Member to Board of Directors
PR Newswire - Fri Feb 28, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo" , a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Michael M. Goldberg, M.D., has been appointed to Echo's Board of Directors.
Mycosis Fungoides - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 10, 2:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/x4qbsj/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2013" report to their offering. 'Mycosis Fungoides - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mycosis Fungoides, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycosis Fungoides. Scope - A snapshot of the global therapeutic scenario for Mycosis Fungoides. - A review of the Mycosis Fungoides products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mycosis Fungoides pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mycosis Fungoides Overview Therapeutics Development Pipeline Products for Mycosis Fungoides - Overview Pipeline Products for Mycosis Fungoides - Comparative Analysis Mycosis Fungoides - Therapeutics under Development by Companies Mycosis Fungoides - Therapeutics under Investigation by Universities/Institutes Mycosis Fungoides - Pipeline Products Glance Late Stage Products Clinical Stage Products Mycosis Fungoides - Products under Development by Companies Mycosis Fungoides - Products under Investigation by Universities/Institutes Mycosis Fungoides - Companies Involved in Therapeutics Development Mycosis Fungoides - Therapeutics Assessment Drug Profiles interferon gamma-1a - Drug Profile brentuximab vedotin - Drug Profile brentuximab vedotin - Drug Profile methotrexate-AzoneTS - Drug Profile Genetically Modified T Cells-1138 - Drug Profile CIGB-128 - Drug Profile Mycosis Fungoides - Recent Pipeline Updates Mycosis Fungoides - Product Development Milestones Featured News & Press Releases List of Tables List of Figures Companies Mentioned Shionogi & Co., Ltd. Seattle Genetics, Inc. Echo Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/x4..._fungoides About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
FDA Approval for DexCom's G4 PLATINUM - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 4:10PM CST
DexCom G4 PLATINUM gets FDA approval for use in children affected with diabetes aged between 2 and 17 years.
IRadimed (IRMD) Jumps: Stock Moves 7.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:25AM CDT
IRadimed (IRMD) was a big mover last session, with shares rising over 7% on the day.
Mazor Robotics (MZOR) Jumps: Stock Moves 6.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 8:25AM CDT
Mazor Robotics (MZOR) was a big mover last session, with shares rising nearly 7% on the day.
The Zacks Analyst Blog Highlights: Medtronic, Covidien, Bacterin International Holdings, Inogen and Echo Therapeutics
PR Newswire - Wed Sep 03, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Medtronic Inc. (NYSE:MDT-Free Report), Covidien plc (NYSE:COV-Free Report), Bacterin International Holdings, Inc. (AMEX:BONE-Free Report), Inogen, Inc. (Nasdaq:INGN-Free Report) and Echo Therapeutics, Inc. (Nasdaq:ECTE-Free Report).
3 Top-Ranked Medical Equipment Stocks to Buy Now - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 1:08PM CDT
The fiscal 2015 budget for the Department of Health and Human Services (HHS) has brought a fresh lease on life to the U.S. healthcare economy, following the past years' debacle.
Echo Therapeutics Sees Narrower Loss but Lags Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 8:20AM CDT
Thanks to the cost reduction measures that were successfully implemented in September last year by Echo Therapeutics (ECTE)
Echo Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Thu Aug 14, 3:30PM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced its financial results for the quarter ended June 30, 2014 and provided a business update. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, is available by visiting the Investors section of Echo's website at www.echotx.com.
Platinum Delivers Letter To Echo Therapeutics, Inc. Demanding To Inspect Certain Books And Records Under Delaware Law
PR Newswire - Wed Jul 23, 6:44PM CDT
An affiliate of Platinum Management (NY) LLC ("Platinum"
has delivered a letter to Echo pursuant to Section 220 of the Delaware General Corporation Law demanding to inspect certain books and records of Echo Therapeutics, Inc. ("Echo" or the "Company" (NASDAQ: ECTE) relating to possible mismanagement, breaches of fiduciary duty and wrongdoing by, among others, members of the Board and the Company's current interim CEO, Kimberly A. Burke. Platinum, together with certain of its affiliates, is the largest stockholder of the Company owning approximately 30% of the outstanding Common Stock on a fully converted basis. Platinum Reports On Town Hall Meeting For Echo Therapeutics, Inc. Stockholders
PR Newswire - Tue Jul 22, 10:26AM CDT
Platinum Management (NY) LLC and certain affiliates ("Platinum"
, which beneficially hold approximately 30.34% of the shares of Echo Therapeutics, Inc. ("Echo" or the "Company" (NASDAQ: ECTE) on a fully converted basis, today reported on the Town Hall Meeting it recently hosted for the concerned stockholders of Echo. All Company directors and stockholders were invited to attend the Town Hall Meeting, but sadly directors Vincent D. Enright, William F. Grieco and James F. Smith (the "Lingering Directors" did not participate despite the dire need for immediate change at Echo. Disturbing Self-Dealing By Repudiated Echo Directors Forces Platinum To Exercise Contractual Right To Call Special Meeting; Town Hall Meeting Also Planned
PR Newswire - Thu Jul 10, 4:14PM CDT
Platinum Management (NY) LLC and certain affiliates ("Platinum"
, the largest stockholder of Echo Therapeutics, Inc. (NasdaqCM: ECTE) ("Echo" or the "Company" owning approximately 20% of the Company's outstanding Common Stock, sent a letter to the Company today exercising Platinum's contractual right under the December 10, 2013 Stock Purchase Agreement between Platinum and the Company to cause Echo to call a meeting of stockholders to vote to lift the "blockers" limiting Platinum's voting power. Echo Announces Election Of New Board Member At Annual Meeting Of Stockholders
PR Newswire - Thu Jun 19, 3:07PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that, based on preliminary results provided by Echo's proxy solicitor, stockholders have elected Shepard M. Goldberg as a new member of the Echo Board of Directors at the 2014 Annual Meeting of Stockholders held on Thursday, June 19, 2014. These preliminary results are subject to receipt of the official confirmation by the independent inspector of elections, IVS Associates, Inc., which is expected to be received early next week.
Echo Therapeutics, Inc. Announces 2013 Financial Results
PR Newswire - Thu Mar 27, 6:50AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced financial results for the year ended December 31, 2013. Echo's Annual Report on Form 10-K, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com on March 28, 2014 after the close of the financial markets.
Echo Therapeutics Schedules 2013 Financial Results for Thursday, March 27, 2014
PR Newswire - Thu Mar 20, 8:35AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it will release financial results for the year ended December 31, 2013 on Thursday, March 27, 2014. Management will hold a conference call to review the company's 2013 performance starting at 9:00 a.m. ET on the same day.
4 Stocks Under $10 Making Big Moves
at The Street - Mon Mar 17, 6:46AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Echo Therapeutics to Exhibit at the ISICEM 2014 Critical Care Conference
PR Newswire - Thu Mar 06, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"
, a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its clinical study of Symphony was selected for poster presentation at the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM) from March 18-21, 2014 in Brussels, Belgium. Echo Therapeutics to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Mon Mar 03, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"
, a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics, will present at the upcoming 26th Annual ROTH Capital Conference. Echo Therapeutics names Michael M. Goldberg to board
M2 - Mon Mar 03, 6:33AM CST
Us-based medical device company Echo Therapeutics Inc (Nasdaq:ECTE) announced on Friday the appointment of Michael M Goldberg, MD, to the company's board of directors.
Echo Therapeutics elects Dr Michael M. Goldberg to board
M2 - Mon Mar 03, 5:21AM CST
Medical device company Echo Therapeutics (NasdaqCM:ECTE) revealed on Friday that Dr Michael M. Goldberg, MD has been appointed to its board of directors.
Echo Therapeutics Adds New Member to Board of Directors
PR Newswire - Fri Feb 28, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"
, a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Michael M. Goldberg, M.D., has been appointed to Echo's Board of Directors. Mycosis Fungoides - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 10, 2:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/x4qbsj/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2013" report to their offering. 'Mycosis Fungoides - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mycosis Fungoides, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycosis Fungoides. Scope - A snapshot of the global therapeutic scenario for Mycosis Fungoides. - A review of the Mycosis Fungoides products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mycosis Fungoides pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mycosis Fungoides Overview Therapeutics Development Pipeline Products for Mycosis Fungoides - Overview Pipeline Products for Mycosis Fungoides - Comparative Analysis Mycosis Fungoides - Therapeutics under Development by Companies Mycosis Fungoides - Therapeutics under Investigation by Universities/Institutes Mycosis Fungoides - Pipeline Products Glance Late Stage Products Clinical Stage Products Mycosis Fungoides - Products under Development by Companies Mycosis Fungoides - Products under Investigation by Universities/Institutes Mycosis Fungoides - Companies Involved in Therapeutics Development Mycosis Fungoides - Therapeutics Assessment Drug Profiles interferon gamma-1a - Drug Profile brentuximab vedotin - Drug Profile brentuximab vedotin - Drug Profile methotrexate-AzoneTS - Drug Profile Genetically Modified T Cells-1138 - Drug Profile CIGB-128 - Drug Profile Mycosis Fungoides - Recent Pipeline Updates Mycosis Fungoides - Product Development Milestones Featured News & Press Releases List of Tables List of Figures Companies Mentioned Shionogi & Co., Ltd. Seattle Genetics, Inc. Echo Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/x4..._fungoides About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
FDA Approval for DexCom's G4 PLATINUM - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 4:10PM CST
DexCom G4 PLATINUM gets FDA approval for use in children affected with diabetes aged between 2 and 17 years.
